{"id":"https://openalex.org/W4361889112","doi":"https://doi.org/10.1158/1078-0432.22477391","title":"Figure S2 from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors","display_name":"Figure S2 from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361889112","doi":"https://doi.org/10.1158/1078-0432.22477391"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22477391","doi":"https://doi.org/10.1158/1078-0432.22477391","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22477391","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Safety_and_Clinical_Activity_of_MEDI0562_a_Humanized_OX40_Agonist_Monoclonal_Antibody_in_Adult_Patients_with_Advanced_Solid_Tumors/22477391/1/files/39928892.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Safety_and_Clinical_Activity_of_MEDI0562_a_Humanized_OX40_Agonist_Monoclonal_Antibody_in_Adult_Patients_with_Advanced_Solid_Tumors/22477391/1/files/39928892.pdf","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110967559","display_name":"Bonnie S. Glisson","orcid":"https://orcid.org/0009-0006-7320-2940","observed_orcids":["https://orcid.org/0009-0006-7320-2940"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bonnie S. Glisson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064621435","display_name":"Rom S. Leidner","orcid":"https://orcid.org/0000-0003-0788-7938","observed_orcids":["https://orcid.org/0000-0003-0788-7938"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rom S. Leidner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086074491","display_name":"Robert Louis Ferris","orcid":"https://orcid.org/0000-0001-6605-2071","observed_orcids":["https://orcid.org/0000-0001-6605-2071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert L. Ferris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090977453","display_name":"John D. Powderly","orcid":"https://orcid.org/0000-0002-7608-0380","observed_orcids":["https://orcid.org/0000-0002-7608-0380"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Powderly","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7608-0380","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075877134","display_name":"Naiyer A. Rizvi","orcid":"https://orcid.org/0000-0002-1134-7494","observed_orcids":["https://orcid.org/0000-0002-1134-7494"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naiyer A. Rizvi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1134-7494","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080295544","display_name":"Bhumsuk Keam","orcid":"https://orcid.org/0000-0001-8196-4247","observed_orcids":["https://orcid.org/0000-0001-8196-4247","https://orcid.org/0000-0002-2974-675X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bhumsuk Keam","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053736790","display_name":"Reva Schneider","orcid":"https://orcid.org/0009-0003-5570-7601","observed_orcids":["https://orcid.org/0009-0003-5570-7601"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Reva Schneider","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029455802","display_name":"Sanjay Goel","orcid":"https://orcid.org/0000-0002-2798-7568","observed_orcids":["https://orcid.org/0000-0002-2798-7568"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sanjay Goel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2798-7568","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071784890","display_name":"James P. Ohr","orcid":"https://orcid.org/0000-0002-7037-6404","observed_orcids":["https://orcid.org/0000-0002-7037-6404"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James P. Ohr","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Jennifer Burton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Burton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101185222","display_name":"Yanan Zheng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yanan Zheng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054978978","display_name":"Steven Eck","orcid":"https://orcid.org/0000-0001-6074-8430","observed_orcids":["https://orcid.org/0000-0001-6074-8430"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven Eck","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074437457","display_name":"Matthew Gribbin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew Gribbin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082831559","display_name":"Katie L. Streicher","orcid":"https://orcid.org/0000-0003-1684-2301","observed_orcids":["https://orcid.org/0000-0003-1684-2301"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katie Streicher","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104956106","display_name":"Danielle Michelle Townsley","orcid":"https://orcid.org/0009-0008-6400-8841","observed_orcids":["https://orcid.org/0009-0008-6400-8841"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danielle M. Townsley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5070734531","display_name":"Sandip Pravin Patel","orcid":"https://orcid.org/0000-0002-8387-4840","observed_orcids":["https://orcid.org/0000-0002-8387-4840","https://orcid.org/0000-0002-4954-4944"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandip Pravin Patel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9301999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9301999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.021700000390410423,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.021700000390410423,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ox40-agonist","display_name":"OX40 agonist","score":0.949999988079071},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.9359999895095825},{"id":"https://openalex.org/keywords/anti-drug-antibody","display_name":"anti-drug antibody","score":0.6639999747276306},{"id":"https://openalex.org/keywords/concentration-time-profiles","display_name":"concentration-time profiles","score":0.7720000147819519},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.597000002861023},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8799999952316284},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.4830000102519989}],"concepts":[{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7092189788818359},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6402983069419861},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5263349413871765},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4805517792701721},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4791635572910309},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4120033085346222},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37999922037124634},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2579183876514435},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.21813654899597168}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.22477391","doi":"https://doi.org/10.1158/1078-0432.22477391","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22477391","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Safety_and_Clinical_Activity_of_MEDI0562_a_Humanized_OX40_Agonist_Monoclonal_Antibody_in_Adult_Patients_with_Advanced_Solid_Tumors/22477391/1/files/39928892.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22477391","doi":"https://doi.org/10.1158/1078-0432.22477391","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22477391","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Safety_and_Clinical_Activity_of_MEDI0562_a_Humanized_OX40_Agonist_Monoclonal_Antibody_in_Adult_Patients_with_Advanced_Solid_Tumors/22477391/1/files/39928892.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361889112.pdf","grobid_xml":"https://content.openalex.org/works/W4361889112.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362418382","https://openalex.org/W4361888884","https://openalex.org/W4362432582","https://openalex.org/W2898194176","https://openalex.org/W4362414850","https://openalex.org/W2588032129","https://openalex.org/W4361946741","https://openalex.org/W4282939568","https://openalex.org/W2745233424","https://openalex.org/W4416903011"],"abstract_inverted_index":{"Figure":[0],"S2:":[1],"Concentration-time":[2],"profiles":[3],"by":[4],"ADA":[5],"status":[6]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-04-05T00:00:00"}